MVT-602 (other developmental code names RVT-602, TAK-448) is a kisspeptin receptor agonist which is under development for the treatment of female infertility and hypogonadism. It has been found to increase luteinizing hormone levels in premenopausal women. As of March 2021, MVT-602 is in phase 2 clinical trials for the treatment of female infertility and hypogonadism. It was also under development for the treatment of prostate cancer, but development for this indication was discontinued.
Property | Value |
---|---|
dbo:abstract |
|
dbo:casNumber |
|
dbo:chEMBL |
|
dbo:drugbank |
|
dbo:fdaUniiCode |
|
dbo:pubchem |
|
dbo:thumbnail | |
rdf:type | |
rdfs:comment |
|
owl:sameAs | |
foaf:depiction | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of |